Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

2.

RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.

Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW.

Oncotarget. 2016 Nov 29;7(48):79869-79884. doi: 10.18632/oncotarget.13084.

3.

Synthesis of a stable and orally bioavailable englerin analogue.

Fash DM, Peer CJ, Li Z, Talisman IJ, Hayavi S, Sulzmaier FJ, Ramos JW, Sourbier C, Neckers L, Figg WD, Beutler JA, Chain WJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2641-4. doi: 10.1016/j.bmcl.2016.04.016. Epub 2016 Apr 8.

4.

Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 expression.

Yurdagul A Jr, Sulzmaier FJ, Chen XL, Pattillo CB, Schlaepfer DD, Orr AW.

J Cell Sci. 2016 Apr 15;129(8):1580-91. doi: 10.1242/jcs.182097. Epub 2016 Feb 18.

5.

Neopetrocyclamines A and B, polycyclic diamine alkaloids from the sponge Neopetrosia cf exigua.

Liang Z, Sulzmaier FJ, Yoshida WY, Kelly M, Ramos JW, Williams PG.

J Nat Prod. 2015 Mar 27;78(3):543-7. doi: 10.1021/np500759r. Epub 2015 Jan 13.

6.

Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties.

Fernández-Gallardo J, Elie BT, Sulzmaier FJ, Sanaú M, Ramos JW, Contel M.

Organometallics. 2014 Nov 24;33(22):6669-6681. Epub 2014 Oct 30.

7.

FAK in cancer: mechanistic findings and clinical applications.

Sulzmaier FJ, Jean C, Schlaepfer DD.

Nat Rev Cancer. 2014 Sep;14(9):598-610. doi: 10.1038/nrc3792. Epub 2014 Aug 7. Review.

8.

FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD.

Mol Cancer Ther. 2014 Aug;13(8):2050-61. doi: 10.1158/1535-7163.MCT-13-1063. Epub 2014 Jun 4.

9.

Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD.

Gynecol Oncol. 2014 Jul;134(1):104-11. doi: 10.1016/j.ygyno.2014.04.044. Epub 2014 Apr 27.

10.

RSK isoforms in cancer cell invasion and metastasis.

Sulzmaier FJ, Ramos JW.

Cancer Res. 2013 Oct 15;73(20):6099-105. doi: 10.1158/0008-5472.CAN-13-1087. Epub 2013 Oct 4. Review.

11.

Englerin a selectively induces necrosis in human renal cancer cells.

Sulzmaier FJ, Li Z, Nakashige ML, Fash DM, Chain WJ, Ramos JW.

PLoS One. 2012;7(10):e48032. doi: 10.1371/journal.pone.0048032. Epub 2012 Oct 22.

12.

RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration.

Gawecka JE, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Heikkilä MM, Matter ML, Ramos JW.

J Biol Chem. 2012 Dec 21;287(52):43424-37. doi: 10.1074/jbc.M112.423046. Epub 2012 Nov 1.

13.

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW.

Int J Cancer. 2012 Oct 1;131(7):1556-68. doi: 10.1002/ijc.27415. Epub 2012 Jan 31.

14.

PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D.

Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW.

Oncogene. 2012 Jul 26;31(30):3547-60. doi: 10.1038/onc.2011.514. Epub 2011 Nov 21.

15.

High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression.

Andersen G, Burkon A, Sulzmaier FJ, Walker JM, Leckband G, Fuhst R, Erbersdobler HF, Somoza V.

Mol Nutr Food Res. 2011 Aug;55(8):1197-206. doi: 10.1002/mnfr.201100292. Epub 2011 Jul 5.

PMID:
21732533
16.

Stictamides A-C, MMP12 inhibitors containing 4-amino-3-hydroxy-5-phenylpentanoic acid subunits.

Liang Z, Sorribas A, Sulzmaier FJ, Jiménez JI, Wang X, Sauvage T, Yoshida WY, Wang G, Ramos JW, Williams PG.

J Org Chem. 2011 May 20;76(10):3635-43. doi: 10.1021/jo200241h. Epub 2011 Apr 18.

17.

Bit-1 mediates integrin-dependent cell survival through activation of the NFkappaB pathway.

Griffiths GS, Grundl M, Leychenko A, Reiter S, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Ramos JW, Matter ML.

J Biol Chem. 2011 Apr 22;286(16):14713-23. doi: 10.1074/jbc.M111.228387. Epub 2011 Mar 7.

18.

The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling.

Pastorino S, Renganathan H, Caliva MJ, Filbert EL, Opoku-Ansah J, Sulzmaier FJ, Gawecka JE, Werlen G, Shaw AS, Ramos JW.

FASEB J. 2010 Aug;24(8):2818-28. doi: 10.1096/fj.09-144295. Epub 2010 Mar 30.

Supplemental Content

Loading ...
Support Center